timeline

Dodgers’ Blake Snell scheduled for surgery, return date unclear

Blake Snell will have surgery Tuesday to remove the loose bodies in his left elbow, according to Dodgers manager Dave Roberts.

Roberts didn’t know which type of surgery Snell will undergo, but there’s optimism that Snell could undergo a minimally invasive procedure, like the one Dr. Neal ElAttrache performed on Tigers ace Tarik Skubal using new NanoNeedle scope technology, according to people with knowledge of the situation not authorized to speak publicly about the matter.

However, it may not be possible to determine the details of Snell’s procedure before getting an internal view. The exact location of the loose bodies plays a large role in the technique.

If Snell is indeed a candidate for the NanoNeedle Scope 2.0, it could cut down his recovery time by minimizing the damage to the surrounding tissue, compared to a traditional arthroscope.

Because the technology is new, it would still be difficult to put an exact timeline on the recovery. Skubal would be the blueprint. He had a bone chip removed a week and a half ago and is already progressing in a throwing program.

Either way, the Dodgers should have a clearer picture of Snell’s recovery timetable after he undergoes the procedure Tuesday.

The Dodgers scratched him from Friday’s start, only his second of the season, and they backdated the IL move to May 12. The two-time Cy Young Award winner started the season on the injured list, ramping up later than usual due to what the team called left shoulder fatigue. In his first start against the Braves last week, he only pitched three innings, giving up four earned runs.

Source link

Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization (NASDAQ:EXEL)

Earnings Call Insights: Exelixis (EXEL) Q1 2026

Management View

  • Michael Morrissey (CEO, President & Director) said the company’s strategy is “to build a multi-franchise business in solid tumor oncology focused on GU and GI histologies,” anchored by cabozantinib and “the potential breadth of the zanzalitinib opportunity,” and added that “CABOMETYX

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Source link